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Abstract
Current advances in basic stem cell research and tissue engineering augur well for the development of improved
cultured skin tissue substitutes: a class of products that is still fraught with limitations for clinical use. Although the
ability to grow autologous keratinocytes in-vitro from a small skin biopsy into sheets of stratified epithelium (within
3 to 4 weeks) helped alleviate the problem of insufficient donor site for extensive burn, many burn units still have
to grapple with insufficient skin allografts which are used as intermediate wound coverage after burn excision.
Alternatives offered by tissue-engineered skin dermal replacements to meet emergency demand have been used
fairly successfully. Despite the availability of these commercial products, they all suffer from the same problems of
extremely high cost, sub-normal skin microstructure and inconsistent engraftment, especially in full thickness burns.
Clinical practice for severe burn treatment has since evolved to incorporate these tissue-engineered skin substitutes,
usually as an adjunct to speed up epithelization for wound closure and/or to improve quality of life by improving
the functional and cosmetic results long-term. This review seeks to bring the reader through the beginnings of skin
tissue engineering, the utilization of some of the key products developed for the treatment of severe burns and the
hope of harnessing stem cells to improve on current practice.
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Background
Despite the recent question on whether skin is the
largest organ in the human body [1], no one can
dispute its protective, perceptive, regulatory and cos-
metic functions. The top layer of the skin, the epi-
dermis which comprised mainly of keratinocytes, is
critical for survival as it provides the barrier against
exogenous substances, chemicals, pathogens and pre-
vents dehydration through the regulation of fluid
loss. Other cells within the epidermis include mela-
nocytes which give pigmentation and Langerhans’
cells which provide immune surveillance. Beneath
the epidermis, the dermis is a thicker layer of con-
nective tissues that consists mainly of extracellular
matrix (ECM) or structural components (predomin-
antly collagen and elastin) which give mechanical
strength, elasticity and a vascular plexus for skin
nourishment. Cells interspersed within the ECM in-
clude fibroblasts, endothelial cells, smooth muscle
cells and mast cells [2]. These two morphologically
distinct layers — the epidermis and the dermis —
are in constant communication across various levels
(example at the molecular or cellular level, growth
factor exchange, paracrine effects, etc.) to establish,
maintain, or restore tissue homeostasis. Between the
epidermis and dermis is the basement membrane
(BM), a highly specialized ECM structure (composed
of a set of distinct glycoproteins and proteoglycans)
that physically separates the two layers rendering
primarily a stabilizing though still dynamic interface
and a diffusion barrier [3]. In general, the BM con-
tains at least one member of the four protein fam-
ilies or subtypes of laminin, type IV collagen,
nidogen, and perlecan, a heparan sulfate proteoglycan [4].
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Populating the epidermal and dermal layers are the
various skin appendages such as the hair follicles,
sweat glands, sebaceous glands, blood vessels and
nerves.
Extreme loss of skin function and structure due to
injury and illness will result in substantial physio-
logical imbalance and may ultimately lead to major
disability or even death. As much as it is claimed that
tissue-engineered skin is now a reality to treat severe
and extensive burns, the fact remains that current
skin substitutes available are still fraught with limita-
tions for clinical use. This is clearly evident amongst
burns or wound-care physicians that there is currently
no single tissue-engineered substitute which can fully
replicate the spilt-thickness skin autografts for per-
manent coverage of deep dermal or full thickness
wounds in a one-step procedure. Indeed, clinical practice
for severe burn treatments have since evolved (Fig. 1) to
incorporate some of these tissue-engineered skin substi-
tutes (Table 1), usually as an adjunct to speed up epitheli-
sation for wound closure and/or to improve quality of life
by improving functional and cosmetic results long-term.
However, we must not lose hope, relook at our current
practices, press on with innovation and develop new strat-
egies in biology, material science and technological know-
how as we seek to achieve the holy grail of creating a fully
functional tissue-engineered composite skin with append-
ages for the clinics.
Review
Birth of skin tissue engineering
A coincidence?
The year 1975 seems to be a special year for skin tissue
engineering, even before the term “tissue engineering”
was officially adopted more than a decade later by the
Washington National Science Foundation bioengineer-
ing panel meeting in 1987 [5] and later its definition elu-
cidated further by Langer and Vacanti [6] in 1993. The
beginnings of skin tissue engineering can be attributed
to the pioneering work of two groups in the United
States forty years ago. First, Rheinwald and Green re-
ported the successful serial cultivation of human epider-
mal keratinocytes in vitro [7] in 1975 and later made
possible the expansion of these cells into multiple epi-
thelia suitable for grafting [8] from a small skin biopsy.
In today’s term, the work is termed “tissue engineering
of the skin epidermis”. Concurrently, Yannas, Burke and
colleagues reported their maiden work on the in vitro
and in vivo characterization of collagen degradation rate
[9] in 1975 which we believe pave the way for the design
of artificial biological dermal substitute [10], resulting in
the “tissue engineering of the skin dermis”.
Another coincidence?
Interestingly, six years later in 1981, both groups inde-
pendently reported the clinical use of their respective
tissue-engineered substitutes for the treatment of severe
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Fig. 1 Timeline of skin tissue engineering in burn surgery
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and extensive burns, albeit in different approaches.
O’Connor et al. reported the world’s first grafting of ex-
tensive burns with sheets of cultured epithelium (ex-
panded from autologous epidermal cells) on two adult
patients with success at the Peter Bent Brigham Hospital
[11, 12]. These autologous cultured sheets (Fig. 2)
termed cultured epidermal autografts (CEA) were also
subsequently demonstrated to provide permanent cover-
age of extensive full thickness burns in another two
paediatric patients [13].
Meanwhile, Burke et al. (a few months after O’Connor
et al.’s report) reported the successful use of a physiolo-
gically acceptable artificial dermis in the treatment of ex-
tensive burn injuries with full thickness component on
ten patients [14]. This was followed by a randomized
clinical trial for major burns led by Heimbach et al. [15]
on the use of this artificial dermis, now known as Inte-
graTM Dermal Regeneration Template. This successful
multi-centre study involving eleven centres and many
other studies [16, 17] might have inevitably given this
dermal substitute a “gold standard” status for full thick-
ness burns treatment [18].
While ground breaking, the work of the above two
groups are still far from reaching the ultimate goal of re-
placing skin autografts for permanent coverage of deep
dermal or full thickness wounds in extensive burns.
Fig. 2 Cultured epithelial autograft supported on a fibrin mat [38]
used at the Singapore General Hospital Burns Centre to treat
major burns
Table 1 Tissue-engineered skin substitutes and current surgical techniques
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CEA: a bumpy ride for prevalence in the clinics
Importance of Cuono’s method
One of the main disadvantages of the CEA technology
was apparently the lack of consistency in engraftment,
with poor “take” reported mainly on wounds devoid of
dermal elements, even with properly cultured keratino-
cytes [19–22]. It was later demonstrated in the mid-
1980s by Cuono and his colleagues on the importance of
having the dermal component present when they re-
ported good graft take of the CEA laid on healthy vascu-
larized allogeneic dermis in a full thickness wound bed
[23, 24]. For the Cuono’s method to be effective, a two-
stage procedure is required. First, there must be available
human skin allografts ready to be grafted on excised full
thickness wound. This is followed by a wait of about two
to three weeks which would provide the patient with ne-
cessary protection and coverage as the underlying ca-
daver dermis vascularizes while the autologous epithelial
sheets from the harvested small skin biopsy can be pre-
pared simultaneously by culture. When the cultures are
ready, the highly immunogenic cadaver epidermis placed
on the patient earlier will have to be removed by derm-
abrasion to make way for the CEA to be grafted (Fig. 3).
This two-stage composite allodermis/cultured autograft
technique has been adopted by several centres with fairly
reproducible success since the 1990s [25–27]. One rela-
tively recent success story came from the Indiana Uni-
versity experience that reported a final graft take of
72.7 % with a 91 % overall survival rate on eighty-eight
severe burn patients. These results as the authors men-
tioned “gives much optimism for continuing to use CEA
in critically burned patient” [28].
The detractors
However, there are still detractors to this Cuono’s
method for a number of reasons. Firstly, there might not
be readily available skin allografts, especially in the East
Asian region where organ and tissue donation is still not
prevalent [29, 30]. In addition, skin allografts carry some
risks of infection and antigen exposure [31]. Secondly,
the timing of the CEA placement could be a tricky bal-
ancing act. It was mentioned that if cadaver skin or epi-
thelium is rejected or sloughed off prior to the
availability of cultured epidermal grafts for the burn pa-
tients, the opportunity to use the cadaver dermis as vas-
cularized dermal support (based on Cuono’s method)
might be lost [32]. The coordination of CEA use with
the timing of surgery is therefore a concern. In another
scenario, the wound bed might be ready for CEA graft-
ing but yet the cultured keratinocytes were not ready or
sufficient for grafting. On the other hand, there were sit-
uations where the CEA cultures were ready for grafting
but the wound bed was not or the patient was too sick
to undergo surgery. It is known that once the keratino-
cytes form a sheet in culture, the sheets need to be used
within the shortest time as possible to maintain efficacy
especially for treatment of full thickness burns [28, 33].
Otherwise, the keratinocyte stem cell population in the
cultures would be compromised and these critical cells
for regeneration would move towards an irreversible
unidirectional process from holoclones (stem cells) to
paraclones (highly differentiated cells) [34–36]. In such a
case, the efficacy of the CEA would drop drastically, ren-
dering poor engraftment and sub-optimal wound healing
[37]. Even though there was a recommendation to use
colony forming efficiency assay of keratinocytes (Fig. 4)
as an indirect and simple quality check for the “regen-
erative property” of CEA cultures [36, 38], there were
not too many adopters.
CEA sheets are fragile in nature and extreme care
must be taken to avoid tangential and shearing forces
while moving the patient’s limb or repositioning the pa-
tient to prevent any loss of the cell layers. Therefore not
surprising, it was reported that CEAs placed on anterior
sites were amendable to improved take rates [28]. How-
ever with the need to keep the grafted site completely
immobile [39] and given the limited sites for grafting of
CEAs (recommended to be placed on “non-pressure
sites” to prevent shearing off of these friable grafts),
these led to some form of resistance to CEA use by
Fig. 3 Grafting of cultured epithelial autografts on allodermis at
Singapore General Hospital Burns Centre based on Cuono’s
two-stage method
Fig. 4 Colony forming efficiency assay: a simple way of measuring
the clonogenic ability of keratinocytes and estimating the growth
capacity of these cells
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certain burn surgeons. In addition, the higher vulner-
ability of CEA to bacterial contamination on the wound
site which could result in almost complete loss of the
grafts compared to meshed autograft [22, 40] also ex-
acerbate the reluctance of CEA use in the clinical
setting.
Issue of cost
Finally, the high cost of production of CEA has often
been quoted as one of the major hindrance for its wide-
spread use in many review papers [37, 39, 41]. This cost
is going to escalate further as there is a trend of direct-
ing cellular therapeutic products with “substantial ma-
nipulation” (this would include keratinocyte expansion)
to be produced in a Good Manufacturing Practice
(GMP) setting for administrative demands like quality,
safety controls and regulations [42]. GMP is a pharma-
ceutical quality system which ensures that products are
consistently produced in a tightly-controlled cleanroom
environment according to stringent quality standards.
Typically, adoption of this practice especially for autolo-
gous human cellular therapeutic products would entail
much higher cost in terms of overheads such as man-
power and facility resources as there is no economy of
scale for such tailored cellular products unlike the
manufacturing of allogeneic cells [43].
Dermal substitutes: a not so bumpy ride for prevalence in
the clinics
Two-stage procedure
Based on the knowledge that there are now many der-
mal substitute products available commercially and with
many of such products widely reviewed and tested in
both pre-clinical and clinical settings [2, 18, 32, 41, 43–
46], it is self-evident that the challenges for their thera-
peutic use (especially for acellular ones) is less than CEA
(cellular-autologous products) insofar as their respective
functional requirements (dermal versus epidermal) are
totally different. If epidermis is “life”: providing the
protection crucial for our survival, then dermis is the
“quality of life”. Most current biocompatible dermal sub-
stitutes are to a certain extent able to mimic the basic
properties of the ECM in the human skin by providing
some form of structural integrity, elasticity and a vascu-
lar bed. However, the fact remains that these products
lack an epithelial layer and in most cases, the use of such
products will need to be followed up with grafting of
split thickness skin autograft for permanent coverage,
usually in a two-stage procedure. While there are advan-
tages of harvesting thinner split-thickness skin autografts
and that donor sites heal faster [15], there is still harvest
site morbidity with a possibility of insufficient donor
sites in extensive burns.
IntegraTM
Being the most widely accepted artificial biological der-
mal substitute [47], the use of IntegraTM which is made
up of bovine collagen and chondroitin 6-sulfate, has
been reported to give good aesthetic and functional out-
comes when compared to using split thickness skin
autograft alone [48]. However, it is known that infection
still remains the most commonly reported complication
of IntegraTM [49–51] . Meticulous wound bed prepar-
ation before the use of this template (or similar type of
artificial biological materials) has been reported to be
critical to ensure good take. Otherwise with the collec-
tion of hematomas and seromas beneath the material,
the product is susceptible to infection resulting in a
costly loss of an expensive tissue-engineered product
and manpower time, while increasing the length of hos-
pital stay for the patient.
But with much progress in the development of newer
wound care products, the use of advanced antimicrobial
silver dressing such as Acticoat dressing as an overlay to
IntegraTM [44] as well as the use of topical negative pres-
sure or vacuum assisted closure (VAC) in combination
with IntegraTM [52–54] have been reported to mitigate
the rates of infection with positive results. In one study,
it was reported that the application of topical negative
pressure dressings to dermal templates can reduce
shearing forces, restrict seroma and haematoma forma-
tion, simplify wound care and improve patient tolerance;
even as it was reported that the negative pressure did
not accelerate vascularization of the Integra dermal tem-
plate based on histological assessment [55].
MatriDerm®
Another newer generation of artificial biological dermal
substitute that is gaining wider acceptance for use in the
clinics recently is MatriDerm®. Made up of bovine colla-
gen and an elastin hydrolysate, this product is touted for
use in a single-stage procedure. MatriDerm® was shown
to be able to accommodate split thickness skin autograft
safely in one step with no compromise in take on burn
injuries [56, 57]; and it seemed to be feasible for use in
critically ill patients [58]. It was suggested that unlike
IntegraTM which has antigenic properties due to the
presence of chondroitin-6-sulfate, the combination of
collagen and elastin in MatriDerm® can promote
vascularization quicker through the support of in-
growth cells and vessels while improving stability and
elasticity of regenerating tissue [44]. Furthermore, higher
rate of degradation and difference in neodermal thick-
ness of MatriDerm® compared to IntegraTM [59] might
give the former an extra edge; even though there is still
relatively weak scientific evidence on their comparison
in the current literature [58].
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Other dermal substitutes
There are also other categories of dermal substitutes
available commercially. On top of substitutes made from
“Artificial Biological Materials” described above for Inte-
graTM and MatriDerm®, the other two commonly recog-
nised classifications are : “Natural Biological Materials”
and “Synthetic Materials” [43, 44]. Decellularized human
skin allografts (such as AlloDerm®) and decellularized
porcine xenografts (such as PermacolTM) are dermal
products derived from “Natural Biological Materials” as
typically these products are “de-epidermalized” and
processed to remove the antigenic cellular components
while retaining the structure of the native dermis.
Known as acellular dermal matrix (ADM), the advantage
of using this class of product is that the templates de-
rived from decellularized tissues provide natural dermal
porosities for regeneration and vascularisation on the
wound bed in-vivo. In vitro studies have shown that
such products support adhesion, growth, and function of
several cell types [60, 61]. In addition, there is partial
conservation of BM which might aid epidermal cell at-
tachment [62]. Nevertheless these products are known
for their high cost with the risk of transmitting infec-
tious diseases and they are usually used in two surgical
procedures [63]. But with advancement in processing of
human skin allografts and also with the use of negative
pressure therapy, studies using a one-stage procedure of
co-grafting with human ADM (CG derm) and autolo-
gous split thickness skin grafts have been reported with
some success [64, 65].
Finally, dermal substitutes using synthetic materials
seem to be less widely used since their inception in the
1990s for burn treatment. Such products include Trans-
cyte®, a porcine collagen-coated nylon mesh seeded with
allogeneic neonatal human foreskin fibroblasts bonded
to a silicon membrane; and Dermagraft®, a bioabsorbable
polyglactin mesh scaffold seeded with cryopreserved
allogeneic neonatal human foreskin fibroblasts. It was
reported that both of these products are currently off
the market but their technologies have been licensed to
Advanced BioHealing for further production and mar-
keting to improve the product [44].
This brings to the issue about cost of dermal substi-
tutes. In general, dermal substitutes are deemed to be
costly for clinical usage as mentioned in a report com-
paring the clinical outcome of MatriDerm® and Inte-
graTM [66]. Based on a tabulated comparison of cost per
cm2 between different dermal substitutes in 2007, it was
noted that DermagraftTM was about twice the cost of
IntegraTM [67], and that might explain why Derma-
graftTM is presently off-market.
Biobrane®
As opposed to Transcyte®, Biobrane® is still widely used
as a synthetic skin substitute as it is known for its suc-
cess in the definitive management of partial thickness
burns (Fig. 5) in many centres [68–70]. Biobrane® is the
exact product of Transcyte® less the neonatal human fi-
broblasts and is also used as a dressing to hold meshed
autografts and cultured keratinocyte suspension [69, 71].
On top of the versatility in usage, the popularity of Bio-
brane® is likely due to its lower cost and yet, it is as effi-
cacious in treating partial thickness burns compared to
Transcyte® [72]. In a recent comparison of Biobrane® and
cadaveric allograft for temporizing the acute burn
wound, Austin et al. concluded that Biobrane® is super-
ior in terms of lower procedural time and associated cost
largely due to the relative ease of application of this
product [73]. Indeed, Greenwood et al. in a sharing of
their experience using Biobrane® on 703 patients con-
cluded that Biobrane® is relatively inexpensive, easy to
store, apply and fix, and reliable when used according to
guidelines [69].
Currently, there is also an increasing trend to use Bio-
brane® as an alternative to cadaver allografts as tempor-
izing dressings after excision of major burn injuries [68,
69, 73]. However, the caveat of using this technique is
that the wound bed must be meticulously prepared to
prevent any infection and there is still the lack of exist-
ing literature and published clinical protocols [68] to
Fig. 5 Application of Biobrane. a. Before application b. After application
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prove that it can be a worthy replacement of the human
skin allografts, especially in the treatment of full thick-
ness burn wounds.
Towards a composite skin substitute for permanent
replacement
Combining CEA and IntegraTM
The first thing that comes to mind for an autologous
composite skin to be used for permanent coverage is to
just individually combine the artificial dermal substitute
(IntegraTM) and the CEA on the wound bed. After all,
both have their roots in 1975 and their first respective
independent clinical use to treat severe burns was re-
ported in 1981. The first hint of their combined use was
in 1984 when Gallico et al. reported the permanent
coverage of large burn wounds with autologous cultured
epithelium in The New England Journal of Medicine
[13]. In the study, it was mentioned that Patient 1 with
flame burns of 97 % total body surface area had received
excision to the level of muscle fascia on certain part of
the body and were covered temporarily by human ca-
daver skin allograft or a collagen-glycoaminoglycans-
silastic sheet (later known as Integra). This was followed
by grafting with CEA even though it was not mentioned
whether the IntegraTM was replaced with the cultured
epithelium. It was only in 1998 that the use of cultured
autologous keratinocytes with Integra in resurfacing of
acute burns was presented in a case report by Pandya et
al. [74]. Used as a two-step procedure, the authors resur-
faced the neodermis (vascularized IntegraTM) by the
third week with ultra-thin meshed autografts and CEA
on the anterior torso of the patient in two mirror-image
halves. It was found that the CEA performed as well as
the side covered with split thickness autograft in terms
of appearance, durability and speed of healing. This posi-
tive result was not surprising as a month earlier in the
same journal, another group [31] reported that vascular-
ized collagen-glycoaminoglycan matrices produced a
favourable substrate for cultured epithelial autografts in
a porcine model.
Interestingly, there were practically no subsequent big-
ger clinical series which describe the two-stage use of
IntegraTM followed by the grafting of CEA. One of the
reasons as alluded by Pandya et al. [74] was that of cost
when they mentioned the combination of IntegraTM and
autologous cultured keratinocytes was very expensive.
The other reason quoted was that direct application of
cultured keratinocytes to an IntegraTM wound bed was
found to be problematic due to the poor adhesion of the
cells to the template [43]. This might be attributed to
the lack of fibroblasts migrated into the IntegraTM which
delayed the maturation of the BM between the epithelial
grafts and the neodermis. In a bilayered skin equivalent
tested in-vitro, the presence of fibroblasts with
keratinocytes was reported to be important for the for-
mation of high levels of collagen type IV and laminin,
some of the key elements of the BM [32, 75]. In fact it
was further validated later in another skin equivalent
model that only in the presence of fibroblasts or of vari-
ous growth factors, laminin 5 and laminin 10/11, nido-
gen, uncein, type IV and type VII collagen (all of which
are components of the BM) were decorating the dermal/
epidermal junction [76].
Combining CEA and other skin substitutes
Similarly it was also observed that there were scanty
clinical reports on the two-stage use of AlloDerm®, (a
decellularized human ADM product that was first ap-
proved by the FDA to treat burns in 1992 [77]) and
CEA. One notable case report in 2009 was the successful
treatment of aplasia cutis congenita using the combin-
ation of first applying on the defect with AlloDerm®
followed by CEA grafting two weeks later. It was re-
ported that during a two-year follow-up period, there
were no complications such as motion limits resulting
from hypertrophic scarring or scar contracture. Coinci-
dentally, there was also an earlier attempt in 2000 to use
allogeneic dermis and CEA as a one-stage procedure to
reconstruct aplasia cutis congenita of the trunk in a
newborn infant [78]. While the results were reported to
be promising, it was noted that three additional applica-
tions of CEAs were required for 90 % of the wound to
be healed.
Autologous dermo-epidermal composite skin substitutes
By far, the most promising autologous dermo-epidermal
(composite) skin substitute reported is the cultured skin
substitutes (CSS) developed in Cincinnati in the United
States. This substitute is composed of collagen-
glycosaminoglycan substrates which contains autologous
fibroblasts and keratinocytes. Reported to be able to pro-
vide permanent replacement of both dermal and epider-
mal layers in a single grafting procedure [2, 79–83], this
product was later commercialised as PermaDermTM
[43]. PermaDermTM can currently be engineered within
30 days. It is indicated for the treatment of large full-
thickness skin defects, however it has not yet obtained
Food and Drug Administration (FDA) approval and clin-
ical trials on its efficacy remain to be seen. More re-
cently, a German group reported the development of an
engraftable tissue-cultured composite skin autograft
using MatriDerm® as a template for the seeding of ex-
panded autologous skin fibroblasts and keratinocytes
[84]. They reported that this developed skin composite
has strong homology to healthy human skin based on
the characterization of the epidermal strata, comparison
of the differentiation and proliferation markers and the
presence of a functional basal lamina. This skin
Chua et al. Burns & Trauma  (2016) 4:3 Page 7 of 14
substitute was subsequently used clinically on two pa-
tients with full thickness wounds. While the wounds are
relatively small in size (the largest being 9 x 6 cm), there
was positive outcome with full wound closure for all the
defects treated [85, 86].
There are many promising autologous cellular
bilayered skin substitutes proposed out there such as
DenovoSkin developed at Tissue Biology Research Unit,
University Children’s Hospital, Zurich, Switzerland. This
product is based on plastically compressed collagen type
I hydrogels engineered with human keratinocytes and fi-
broblasts from a small skin biopsy [87, 88]. The same
group has further reported for the first time, a more ad-
vanced bioengineered human dermo-epidermal skin
graft containing functional dermal blood and lymphatic
vessels using human keratinocytes,fibroblasts, and micro-
vascular endothelial cells [89, 90]. However the challenge
for the utilization of such products remains; that is: how
soon can we culture sufficient autologous cells, impreg-
nate them into the scaffold and get the substitute ready
for grafting. Time is of essence especially for a massive
burn case with little donor site and options.
Adapting the use of skin tissue engineering products to
current practice in the clinics
Combining CEA and widely-meshed autografting
One of the solutions adopted in the clinical setting auto-
grafting to quickly treat extensive full-thickness burn
wounds is to use widely-meshed split thickness skin
grafts to cover the large injured surfaces after the tech-
nique of meshing was introduced by Tanner et al. in
1964 [91]. However at expansion rate greater than 1:4,
such meshed grafts have been reported to be difficult to
handle. Worse still, re-epithelialization might be delayed
or even absent when a meshed piece of skin was ex-
panded beyond a ratio of 1:6 [92]; and with substantial
areas left uncovered in the interstices, there would be
cosmetically unsatisfactory “string vest” appearance [93].
To address these disadvantages, use of CEA in
combination with widely meshed autografts (Fig. 6) has
been reported with success in a clinical series of 12 chil-
dren with major burns. As the authors in the study men-
tioned, this synergistic combination of autografts and
autologous cultured epidermis sheets appeared more ef-
fective than one of these techniques applied alone [94].
Based on the Indiana University experience of eighty-
eight patients who received CEA (an earlier-mentioned
study deemed to be one of the success stories in CEA
usage), the authors also reported that if an insufficient
amount of cadaver dermis remains after allografting
(Cuono’s method), 1:6 meshed split thickness autografts
(if available) would be placed onto recipient wound bed
under the CEA sheets. This was to minimize shear
forces and hasten graft take in areas with inadequate
allodermis [28]. Other variant technique involving the
use of sprayed cultured autologous keratinocytes in
combination with meshed autografts to accelerate
wound closure in difficult-to-heal burn patients was also
reported [95].
Resurgence of microskin autografting
Based on the current literature, there seems to be a re-
surgent towards the use of autologous microskin grafting
(Fig. 7) even though the concept of using small skin bits
for autografting was described by Meek in 1958 [96], be-
fore the use of meshed grafts. Chinese-originated micro-
skin autografting was described in the 1980s for the
treatment of extensive burns [97, 98]. Later in 1993,
Kreis et al. improved on Meek’s original technique [99]
and popularised the so-called modified Meek method
which was found to be superior to widely-meshed auto-
grafts when higher expansion rates (up to 1:9) were used
in adult patients with major burns [100]. While the
modified Meek method or the Chinese-originated micro-
skin grafting method (expansion rate of up to 1:15) is
still time-consuming and laborious with the need for
more staff in the operating theatre [101], these problems
do not seem to serve as a deterrent because this proced-
ure which can be performed almost immediately is seen
as life-saving [102]. Outcome is generally positive with
reliable take rate even on difficult wound bed [103],
shorter epithelization time [101, 104, 105], less prone to
loss due to infection [92, 100] as well as satisfactory
functional and aesthetic results [106–108]. Moreover if
the Meek graft fail, it was restricted to a partial area
without affecting the neighbouring skin islands [103]
formed from the epithelial migration from the borders
of each of the skin bits. More recently, the use of micro-
graft transplantation with immediate 100-fold expansion
for epidermal regeneration on both healthy and diabetic
wounds in porcine models was reported [109]. In the
same report, it was mentioned early clinical results con-
firmed the utility of this technique in a case report of a
Fig. 6 Combining cultured epithelial autografts and widely-meshed
autografts
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civilian patient with fifty-four percent total body surface
area burn admitted to a U.S. Army military hospital in
Iraq and successfully treated with the described micro-
grafting technique [110].
Combining CEA and microskin autografting
However, scar contracture and hypertrophic scar forma-
tion (as would be seen in cases using widely-meshed au-
tografts) are problems frequently associated with
microskin autografting, especially where high expansion
ratios are used for the treatment of extensive burns with
high percentage of deep dermal or full thickness compo-
nent [92, 93]. Therefore as what was described earlier
for widely-meshed skin autografts, CEA was also re-
ported to be used in combination with microskin auto-
grafting to accelerate wound closure [93, 101, 111].
Results reported have been positive with one of the earli-
est studies by Raff et al. describing that the combination
of widely expanded postage stamp split thickness grafts
and CEA provided an excellent take rate and durable
wound closure within a short time while avoiding the
problems associated with engraftment of CEA on fascia
[101]. Menon et al. also reported that with the use of
sprayed CEA and modified Meek technique, they ob-
served no cases of blistering or scar contracture in those
treated sites but unfortunately, the problem of hyper-
trophic scar remained [93].
Modified Meek technique and IntegraTM
The modified Meek technique in combination with Inte-
graTM dermal template in a two-stage procedure has
been reported in extensive burns with some success in a
case report involving three patients [112]. As well, rad-
ical resection and reconstruction of a giant congenital
melanocytic nevus with meek-graft covered Integra was
also reported [113]. However, there are very few reports
that utilised the above described technique subsequently.
On top of cost and issue of infection, it can be specu-
lated that the lack of popularity of this two-stage proced-
ure is that it would incur a delay in utilising the
microskin for epithelization which is the main strength
of the micrografting technique.
Where is the next trajectory?
Stem cells
Advances in research of adult stem cells and embryonic
stem cells offer hope for the therapeutic deficiencies in
severe burn treatment using existing skin tissue-
engineered products. The therapeutic power of stem
cells resides in their clonogenicity and potency [114] and
these can be delivered in conjunction with skin compos-
ites or by various other methods, including direct appli-
cation [115]. More recently, there is a burgeoning
interest in human induced pluripotent stem cells
(hiPSCs) as this Nobel-winning technology pioneered by
Shinya Yamanaka and his team [116, 117] enables the re-
programming of adult somatic cells to embryonic-stage
cells. hiPSCs technology therefore allows for patient-
and disease-specific stem cells to be used for the devel-
opment of therapeutics, including more advanced prod-
ucts for skin grafting and treatment of cutaneous
wounds [115]. However, the recent suspension of the
world’s first clinical trial involving hiPSCs to treat age-
related macular degeneration continues to raise ques-
tions about the safety of this new technology. hiPSCs
often acquire mutations with epigenetic and chromo-
somal changes in culture [118]. Hence, human epider-
mal and mesenchymal stem cells remain the more
promising options for clinical use to treat severe burns,
at least in the near term.
Enriching for epidermal stem cells
Poor engraftment of CEA even on a properly-prepared
vascularised wound bed with dermal element is thought
to be due to epidermal stem cell depletion during graft
preparation. A solution for this would be to start with a
pure population or higher percentage of these stem cells
as suggested by Charruyer and Ghadially [119]. Epider-
mal stem cells can be enriched from the patient’s own
skin and a recent study demonstrated that ABCG2, a
Fig. 7 Microskin autografting on an extensive-burn patient at the Singapore General Hospital Burns Centre. a. Split thickness skin autografts were
cut into small pieces and laid in close proximity with one another on cadaveric allografts. b. Sheets of autologous microskin-allografts were
grafted onto recipient wound bed
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member of the ATP binding cassette (ABC) transporter
family, was a robust stem cell indicator in the human
interfollicular keratinocytes that could potentially be
used to quickly enrich for keratinocyte stem cells [120].
Mavilio et al. showed that sheets of epithelium grown
from autologous holoclones or keratinocyte stem cells
(modified genetically) could be used to treat a patient
with junctional epidermolysis bullosa [121], demonstrat-
ing the power of this graft refinement. The use of
enriched population epidermal stem cells for the prepar-
ation of cultured grafts for patients offers hope of over-
coming several limitations of current skin substitutes as
in a suitable microenvironment, keratinocyte stem cells
can also form appendages such as hair, epidermis and
sebaceous glands [122, 123]. However finding or creating
that elusive microenvironment (in vivo or in vitro) - to
provide the necessary molecular or cellular signals for
the stem cells to regenerate a fully functional skin with
all its appendages - remains a challenge.
Harnessing allogeneic mesenchymal stem cells
During the past decade, adult tissue-derived MSCs have
rapidly moved from in-vitro and animal studies into hu-
man trials as a therapeutic modality for a diverse range
of clinical applications. MSCs raise great expectations in
regenerative medicine, not only because of their multi-
potent differentiation characteristics, trophic and immu-
nomodulatory effects but also for their extensive sources
and biostability when cultured and expanded in vitro
[124]. Apart from bone marrow and adipose tissues, hu-
man MSCs can also be isolated from a variety of other
tissues such as the amniotic membrane [125], umbilical
cord [126, 127], cord blood [128] as well as the hair fol-
licle dermal papilla [129] and sheath [130, 131].
MSCs have demonstrated a number of properties in-
vitro that can promote tissue repair, including the pro-
duction of multiple growth factors, cytokines, collagens,
and matrix metalloproteinases [132, 133] in addition to
the ability to promote migration of other skin cells such
as keratinocytes [134]. MSCs have also been reported to
enhance wound healing through differentiation and
angiogenesis [135]. In the current literature, several clin-
ical cases on the use of cultured autologous bone
marrow MSCs for localized and topical treatment of
chronic wounds have been reported. Yoshikawa et al.
treated twenty patients with various non-healing wounds
(i.e., burns, lower extremity ulcers, and decubitus ulcers)
using autologous bone marrow–derived mesenchymal
stem cells expanded in culture and a dermal replace-
ment with or without autologous skin graft [136]. The
authors reported that 18 of the 20 wounds appeared
healed completely with the cell-composite graft transfer,
and the addition of mesenchymal stem cells facilitated
regeneration of the native tissue by histologic
examination. For allogeneic MSCs usage, Hanson et al.
[137] reported the use allogeneic bone marrow- or
adipose-derived, MSCs to treat partial-thickness wounds
of Göttingen Minipigs and demonstrated the safety,
feasibility and potential efficacy of these MSCs for treat-
ment of wounds.
In our opinion, the immunomodulatory effect of MSCs
is key to the immediate utilization of these cells for rapid
treatment of severe burns. It is now clear that MSCs
modulate both innate and adaptive responses and evi-
dence is now emerging that the local microenvironment
is important for the activation or licensing of MSCs to
become immunosuppressive [138]. Without this prop-
erty, there is no way we can harness the regenerative
and pro-angiogenic effects of the MSCs in the first place.
Thankfully, we can have this off-the-shelf option to use
MSCs as an allogeneic source of cells which can be pre-
tested for safety and potency before use. And as
vascularization of dermal template is crucial for perman-
ent skin graft take - whether in a one-stage or two-stage
procedure, the presence of allogeneic MSCs would def-
initely give that extra edge towards angiogenesis.
It is therefore not surprising to learn that the first
worldwide clinical trial which uses allogeneic bone
marrow MSCs to treat 10 patients with large severe deep
burns is in progress in Argentina. This is done by treat-
ing the wound with the application of MSCs through a
fibrin-based polymer spray over an acellular dermal bio-
logical matrix [139]. The same group, Mansilla et al. has
just reported their preliminary experience treating a pa-
tient with 60 % total body surface burned with positive
results [140]. A search using “allogeneic mesenchymal
stem cells for burns” in ClinicalTrials.gov (as at Nov
2015) also revealed that two of such trials have been
filed [141] which further reinforce the hypothesis that
allogeneic MSCs might have a role in major burn
treatment.
Conclusions
Similar to the what was mentioned that no single treat-
ment can be recommended in the management of dia-
betic foot ulcers based on the current and emerging
therapies [142], there is no particular approach that is
definitely superior for the treatment of severe burns. But
based on existing technologies and products available
for rapid coverage of extensive burns wounds - the use
of Biobrane or similar products to cover the partial
thickness component whilst the coverage of the deep
dermal or full thickness component with skin allografts
after excision, followed by a definite closure with auto-
grafts (meshed, microskin, CEA or in combination) -
seem to be one of the efficacious and cost-effective man-
agement approaches. If the quality of life of the patients
is to be considered such as to reduce scarring and
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contractures, tissue-engineered dermal templates can be
used but they typically come at a cost. Therefore, before
technology can catch up in terms of producing a truly
functional substitute that comes at a reasonable cost, the
need for skin allograft tissue banks, whether local or re-
gional, to serve healthcare centres that treat severe
burns cannot be overstated. This is especially true in the
event of mass casualty [143]. Having a facility that can
double up as both a skin allograft bank and an autolo-
gous epithelial cell sheet culture laboratory would be a
bonus as we seek to train and build up a critical mass of
skin tissue engineers, scientists as well as administrators
specializing in finance, quality assurance and regulatory
affairs. Only by working closely with clinicians to fully
appreciate the requirements for the patients, can this
specialized pool of personnel innovate, harness emerging
technologies, manage cost and navigate through the
regulatory minefields for a realistic advancement of this
exciting field of skin-based regenerative medicine.
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